Survival of pancreatic cancer cells lacking KRAS function
نویسندگان
چکیده
منابع مشابه
KRAS in pancreatic cancer.
Pancreatic cancer is one of the most feared malignancies. The most common form of pancreatic cancer is adenocarcinoma arising from the ductal epithelium. KRAS is the most common oncogene that has been found to be mutated. However, targeting KRAS directly has been difficult. We do not know a lot about the relationship between KRAS and other signaling pathways. At the same time, little is known a...
متن کاملOncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.
Mutational activation of KRas is the first and most frequently detected genetic lesion in pancreatic ductal adenocarcinoma (PDAC). However, the precise role of oncogenic KRas in the pathogenesis of PDAC is not fully understood. Here, we report that the endogenous expression of oncogenic KRas suppresses premature senescence in primary pancreatic duct epithelial cells (PDEC). Oncogenic KRas-media...
متن کاملDysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V-Ki-ras2 Κirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling pathway genes and the association with clinical characteristics in PDAC patients undergoing radi...
متن کامل[A Kras-specific function in cancer initiation].
The three closely related Ras proteins, Kras, Hras and Nras constitute the founding members of the Ras superfamily of small GTPases, which serve as molecular switches that relay extracellular signals to a variety of fundamental cellular processes, including proliferation, survival and differentiation. 1,2 These proteins have been of particular interest to cancer biologists due to the high frequ...
متن کاملMutant KRAS is a druggable target for pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet this challenge, we have developed a local prolonged siRNA delivery system (Local Drug EluteR, LODE...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Communications
سال: 2017
ISSN: 2041-1723
DOI: 10.1038/s41467-017-00942-5